Free Trial
→ Last call for your free 0DTE report (From Profits Run) (Ad)tc pixel
NASDAQ:NKTR

Nektar Therapeutics Q3 2026 Earnings Date & Estimates

Nektar Therapeutics logo
$38.87 -0.31 (-0.79%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$38.75 -0.12 (-0.31%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nektar Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 5:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
5:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Nektar Therapeutics in Q3 2026

Nektar Therapeutics is expected to post earnings of -$2.07 per share on revenue of $10.27 million. In the same quarter a year earlier Nektar Therapeutics reported -$1.85 per share on revenue of $11.79 million. Nektar Therapeutics last reported on August 13, 2026, posting -$1.23 per share and beating the -$1.97 consensus estimate. Nektar Therapeutics has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$2.07
Expected Revenue
$10.27 million
Prior-Year EPS
-$1.85
Prior-Year Revenue
$11.79 million
Expected Revenue Growth
-12.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.23 (Beat by +$0.74)
Last Quarter Revenue
$10.13 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Nektar Therapeutics Q3 2026 Earnings FAQ

Nektar Therapeutics (NASDAQ:NKTR) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Nektar Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 5:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Nektar Therapeutics to post earnings of -$2.07 per share for Q3 2026.

The consensus revenue estimate for Nektar Therapeutics is $10.27 million for Q3 2026.

Nektar Therapeutics Earnings Headlines

Nektar Therapeutics: Focus Returns To The Strengths Of The Company
October 30 at 12:31 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4960288-nektar-therapeutics-focus-returns-to-the-strengths-of-the-company?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets
October 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/nektar-therapeutics-to-announce-financial-results-for-the-third-quarter-on-thursday-november-12-2026-after-close-of-us-based-financial-markets-302921182.html
Last call for your free 0DTE report
The 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, protect it. This report normally sells for 29.97, but it's available as a free download for a limited time.tc pixel
October 31 at 1:00 AM  |  Profits Run (Ad)
Nektar Therapeutics (NKTR) - What Are Researchers Thinking About This Stock?
October 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31157743
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 23, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/nektar-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302918440.html
Leerink Partners initiates coverage of Nektar Therapeutics with outperform rating
October 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/leerink-partners-initiates-coverage-of-nektar-therapeutics-with-outperform-rating/ar-AA2e9BLo
See More Nektar Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nektar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nektar Therapeutics and other key companies, straight to your email.

About Nektar Therapeutics

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company focused on discovering and developing medicines for autoimmune, inflammatory and other serious diseases. The company uses its proprietary biologics and polymer-conjugation technologies to design therapies intended to improve immune-system regulation, drug activity and dosing convenience.

Nektar’s pipeline includes rezpegaldesleukin, an investigational treatment designed to expand regulatory T cells and potentially restore immune tolerance in conditions such as atopic dermatitis, alopecia areata and other autoimmune diseases. The company is also developing NKTR-255, an investigational natural-killer-cell stimulator being studied as a potential treatment for cancer, including in combination with other immunotherapies.

Founded in 1990 as Inhale Therapeutic Systems, Nektar adopted its current name in 2003 and is headquartered in San Francisco, California. Its earlier work in drug-delivery and polyethylene glycol, or PEGylation, technologies supported collaborations and licensed products across multiple therapeutic areas. Nektar is led by President and Chief Executive Officer Howard W. Robin.

View Nektar Therapeutics Profile
Earnings Tools